AstraZeneca has signed an agreement with Roche and Qiagen to
develop two separate diagnostic tests, both using simple blood samples, to find
out patients who will benefit from its lung cancer drugs.
At present, the testing of patients to see if their tumors
contain genetic mutations that make them suitable for drug treatment involves
collecting a sample of tissue by needle biopsy or during surgery.
Toad Venom Slows Cancer Progression
Researchers say that a Chinese medicine made from dried venom secreted by the skin glands of toads has shown promise in slowing down cancer progression in patients.
Advertisement
The new tests are based on smart technology that can find out small fragments of circulating tumor DNA in the plasma taken from patients' blood.
The association with Qiagen involves developing such a test
to accompany AstraZeneca's established lung cancer pill Iressa, while the collaboration
with Roche is for a companion diagnostic to go with AstraZeneca's experimental
successor to Iressa called AZD9291.
![Cell Phone Radiation and Cancer - Unveiling the Link]( "Cell Phone Radiation and Cancer - Unveiling the Link")
Scared after hearing all the harmful effects of cell phone use? Read on to find more about what cell phone radiation actually does and how you can cut down on the exposure.
AZD9291 targets a genetic mutation that helps tumors avoid existing treatments and AstraZeneca believes it could sell a total of $3 billion a year.
The mutation, T790M, develops in about half of lung cancers that become defiant to current epidermal growth factor receptor inhibitors like Iressa.
Source: Medindia
Cell Phone Radiation and Cancer - Unveiling the Link
Scared after hearing all the harmful effects of cell phone use? Read on to find more about what cell phone radiation actually does and how you can cut down on the exposure.
Advertisement
AZD9291 targets a genetic mutation that helps tumors avoid existing treatments and AstraZeneca believes it could sell a total of $3 billion a year.
The mutation, T790M, develops in about half of lung cancers that become defiant to current epidermal growth factor receptor inhibitors like Iressa.
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The reverse vaccine uses the liver's natural "non-target" signals to prevent autoimmune responses against naturally decaying cells.
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
